G1 Therapeutics Inc (GTHX)
4.49
+0.05
(+1.13%)
USD |
NASDAQ |
May 03, 16:00
4.58
+0.09
(+2.00%)
After-Hours: 20:00
G1 Therapeutics Research and Development Expense (Quarterly): 7.38M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 7.38M |
| September 30, 2023 | 8.811M |
| June 30, 2023 | 12.04M |
| March 31, 2023 | 15.48M |
| December 31, 2022 | 16.59M |
| September 30, 2022 | 19.58M |
| June 30, 2022 | 20.84M |
| March 31, 2022 | 26.30M |
| December 31, 2021 | 19.79M |
| September 30, 2021 | 21.14M |
| June 30, 2021 | 18.75M |
| March 31, 2021 | 16.54M |
| December 31, 2020 | 16.37M |
| September 30, 2020 | 17.93M |
| June 30, 2020 | 18.53M |
| March 31, 2020 | 20.43M |
| Date | Value |
|---|---|
| December 31, 2019 | 24.49M |
| September 30, 2019 | 22.94M |
| June 30, 2019 | 23.49M |
| March 31, 2019 | 18.08M |
| December 31, 2018 | 19.08M |
| September 30, 2018 | 15.87M |
| June 30, 2018 | 18.38M |
| March 31, 2018 | 17.35M |
| December 31, 2017 | 15.08M |
| September 30, 2017 | 14.05M |
| June 30, 2017 | 13.67M |
| March 31, 2017 | 11.08M |
| December 31, 2016 | 9.141M |
| September 30, 2016 | 5.695M |
| June 30, 2016 | 6.454M |
| March 31, 2016 | 3.872M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
7.38M
Minimum
Dec 2023
26.30M
Maximum
Mar 2022
18.29M
Average
18.75M
Median
Jun 2021
Research and Development Expense (Quarterly) Benchmarks
| Amicus Therapeutics Inc | 35.03M |
| Geron Corp | 29.37M |
| Palatin Technologies Inc | 5.554M |
| Oragenics Inc | 11.04M |
| TG Therapeutics Inc | 32.72M |